AZN - AstraZeneca PLC
34.65 -0.03 (-0.09%)
After hours: 4:01PM EDT
| Previous Close | 34.61 |
| Open | 34.91 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 34.61 - 34.94 |
| 52 Week Range | 25.55 - 35.60 |
| Volume | 3,489,381 |
| Avg. Volume | 5,003,006 |
| Market Cap | 83.54B |
| Beta | 0.65 |
| PE Ratio (TTM) | 22.73 |
| EPS (TTM) | 1.52 |
| Earnings Date | N/A |
| Dividend & Yield | 0.90 (2.63%) |
| Ex-Dividend Date | 2017-08-09 |
| 1y Target Est | 37.37 |
- Zacks•12 hours ago
Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
Foreign markets remain undeterred by discouraging events, notching up weekly gains.
- Bloomberg•22 hours ago
Drug Companies Fear Brexit Will Hit Medicine Trade
Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.
- Zacks•3 days ago
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
The pharma/biotech sector has a number of things going in its favor.
- Zacks•3 days ago
Cancer Space Update: Lung & Breast Cancer Studies in Focus
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
- Zacks•4 days ago
Lilly's Verzenio Gets Priority Review in First-Line Setting
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
- Zacks•7 days ago
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
- Business Wire•8 days ago
TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation by US FDA for the 1st-Line Treatment of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
AstraZeneca today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for TAGRISSO® for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer .
- Financial Times•8 days ago
[$$] AstraZeneca chief confident risks will pay off
Pascal Soriot is the first to recognise that a pharmaceutical company must take risks if it is to find the next transformative medicine. "It would be much simpler to sell toothbrushes and toothpastes ...
- Motley Fool•9 days ago
What's Behind AstraZeneca's September Rebound?
AstraZeneca's shares finally broke out of their slump in September.
- Investor's Business Daily•13 days ago
These Biotechs Slump As Report Suggests Discounting Their Drugs
AstraZeneca and Tesaro stocks were in a slump Tuesday, a day after an institute doubted the cost-effectiveness of their cancer drugs.
Reuters•15 days agoTell us how Brexit will work, British companies demand
British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.
- Reuters•15 days ago
Drugs firm AstraZeneca wants three-year Brexit transition
British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.
Reuters•15 days agoDrugs firm AstraZeneca wants three-year Brexit transition
British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.
- Simply Wall St.•17 days ago
Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?
AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 21.6x, which is lower than the industry average of 38.5x. While AZN might seem like an attractive stock to buy,Read More...
- Zacks•20 days ago
AstraZeneca's Bevespi Improves Lung Function in Phase III Study
AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.
- Motley Fool•21 days ago
3 High-Yield Stocks for Aggressive Investors
This drugmaker, telecom, and energy company all sport sky-high yields.
- Motley Fool•22 days ago
12 Flu Season Facts You Need to Know
Here's everything you've ever wanted to know about influenza and flu vaccines.
- Motley Fool•24 days ago
AstraZeneca Stock Upgraded: What You Need to Know
Bernstein sees opportunity in a buyout target.
- Zacks•27 days ago
Implied Volatility Surging for AstraZeneca (AZN) Stock Options
AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•28 days ago
3 High-Yield Pharmaceutical Stocks
On the hunt for a fat dividend yield? These three big pharma stocks deliver.
- Zacks•last month
Oncology Space in Focus this Week on ESMO Presentations
There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.
- Business Wire•last month
Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients with Type-2 Diabetes at Wide Range of CV Risk
AstraZeneca today announced full results from the EXSCEL trial that showed cardiovascular safety with Bydureon in patients with type-2 diabetes at a wide range of CV risk.
- Zacks•last month
AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs
AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.
